InterAx Biotech announced today that it has entered an agreement with Lundbeck A/S to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform.
InterAx and Lundbeck will combine their expertise in the characterization of drug candidates for an undisclosed target. “We are delighted to assist Lundbeck in their quest to identify compounds with superior biological properties for their target receptor with our unique technology”, says Maria Waldhoer, CSO at InterAx. Financial terms of the partnership were not disclosed.
InterAx Biotech AG is pioneering computational pharmacology for drug discovery. With this approach in vivo effects of drug candidates can be predicted by analyzing complex experimental in vitro data sets. The Swiss company applies mathematical models and simulations to in house-derived bioanalytical data in order to address the complexity of drug-induced cellular signaling mechanisms.
Denmark-based H. Lundbeck A/S is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, Lundbeck A/S has been at the forefront of research within neuroscience. In 2018 revenue reached more than CHF2.7 billion (DKK 18,117 million) representing an increase of 5% (8% in local currencies) compared to 2017. In March 2018, Lundbeck acquired the Swiss start-up Prexton Therapeutics for up to CHF 1 billion.
(Press release - SK)
Please login or sign up to comment.
Commenting guidelines